Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

被引：4

作者：

Li, Dunhui ^{[1
,2
,3
]}

Mastaglia, Frank L. ^{[1
,2
]}

Yau, Wai Yan ^{[1
]}

Chen, Shengdi ^{[4
,5
]}

Wilton, Steve D. ^{[1
,2
]}

Akkari, Patrick A. ^{[1
,2
,6
]}

机构：

[1] Univ Western Australia, Perron Inst Neurol & Translat Sci, 8 Verdun St, Nedlands, WA 6009, Australia

[2] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Murdoch, WA, Australia

[3] Zhengzhou Univ, Coll Nursing & Hlth, Zhengzhou, Peoples R China

[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China

[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Neurol, Sch Med, Shanghai, Peoples R China

[6] Duke Univ, Dept Neurol, Durham, NC USA

来源：

MOVEMENT DISORDERS | 2022年 / 37卷 / 11期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1002/mds.29201

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：2184 / 2190

页数：7

共 50 条

[31] Astrocytes and Therapeutics for Parkinson's Disease [J].

Rappold, Phillip M. ;

Tieu, Kim .

NEUROTHERAPEUTICS, 2010, 7 (04) :413-423

[32] Cell Therapeutics in Parkinson’s Disease [J].

Olle Lindvall ;

Anders Björklund .

Neurotherapeutics, 2011, 8 :539-548

[33] Cell Therapeutics in Parkinson's Disease [J].

Lindvall, Olle ;

Bjorklund, Anders .

NEUROTHERAPEUTICS, 2011, 8 (04) :539-548

[34] Milestones in Parkinson's Disease Therapeutics [J].

Rascol, Olivier ;

Lozano, Andres ;

Stern, Matthew ;

Poewe, Werner .

MOVEMENT DISORDERS, 2011, 26 (06) :1072-1082

[35] NNR therapeutics for Parkinson's disease [J].

Strachan, Jon-Paul ;

Heemstra, Ronald J. ;

Bhatti, Balwinder S. ;

Akireddy, Srinivasa ;

Murthy, Srinivasa ;

Miao, Lan ;

Mazurov, Anatoly A. ;

Kombo, David C. ;

Speake, Jason D. ;

Letchworth, Sharon R. ;

Jordan, Kristen G. ;

Zhang, Jenny ;

Graef, John D. ;

Szeliga, Ken T. ;

James, John W. ;

Johnston, Tom H. ;

Huot, Philippe ;

Fox, Susan H. ;

Hill, Michael ;

Brotchie, Jonathan M. .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244

[36] Targeted delivery of antisense oligonucleotides to pancreatic β-cells [J].

Ammala, C. ;

Drury, W. J., III ;

Knerr, L. ;

Ahlstedt, I ;

Stillemark-Billton, P. ;

Wennberg-Huldt, C. ;

Andersson, E-M ;

Valeur, E. ;

Jansson-Lofmark, R. ;

Janzen, D. ;

Sundstrom, L. ;

Meuller, J. ;

Claesson, J. ;

Andersson, P. ;

Johansson, C. ;

Lee, R. G. ;

Prakash, T. P. ;

Seth, P. P. ;

Monia, B. P. ;

Andersson, S. .

SCIENCE ADVANCES, 2018, 4 (10)

[37] Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides [J].

Benson, MD ;

Kluve-Beckerman, B ;

Zeldenrust, SR ;

Siesky, AM ;

Bodenmiller, DM ;

Showalter, AD ;

Sloop, KW .

MUSCLE & NERVE, 2006, 33 (05) :609-618

[38] Antisense oligonucleotides for atherosclerotic disease [J].

Bajaj, Archna ;

Rader, Daniel J. .

NATURE MEDICINE, 2020, 26 (04) :471-472

[39] Antisense oligonucleotides for atherosclerotic disease [J].

Archna Bajaj ;

Daniel J. Rader .

Nature Medicine, 2020, 26 :471-472

[40] Antisense oligonucleotides as molecular tools to silence prolonged (CAG)n tracts in Huntington's disease [J].

Vlamings, R. ;

Evers, M. M. ;

van Roon-Mom, W. M. C. ;

Mulders, S. A. M. ;

Janssen, M. L. F. ;

Verheul, R. C. ;

van Deutekom, J. C. T. ;

Temel, Y. .

MOVEMENT DISORDERS, 2012, 27 :S61-S61

← 1 2 3 4 5 →